The Globe and Mail reports in its Thursday, March 7, edition that Raymond James analyst Rahul Sarugaser continues to rate Knight Therapeutics "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Sarugaser bumped his share target up by 50 cents to $7.50. Analysts on average target the shares at $6.56. Mr. Sarugaser says in a note: "Knight Therapeutics is situating itself as the go-to LATAM partner for U.S.- and EU-focused pharma companies looking to capture value from their best-in-class drugs in the region (one of the world's fastest growing pharma markets), potentially driving material (and, importantly, non-binary) positive returns for shareholders. We believe Knight's trusted governance (oversight by Canadian regulators), its formidable on-the-ground infrastructure (more than 650 LATAM FTEs, three manufacturing plants, plus R&D and distribution centres), alongside the strong track record Knight is accruing in the region (securing large contracts from national Ministries of Health) advantages Knight in licensing discussions with future and current pharma/biotech partners seeking to participate in LATAM markets."